539 related articles for article (PubMed ID: 27539727)
1. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
2. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
3. RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.
Wang S; Wang B; Xie C; Ye D
Endocr Pathol; 2019 Dec; 30(4):297-304. PubMed ID: 31494787
[TBL] [Abstract][Full Text] [Related]
4. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
6. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
[TBL] [Abstract][Full Text] [Related]
7. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
8. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
9. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
10. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
[TBL] [Abstract][Full Text] [Related]
11. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
12. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
14. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
15. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC.
Joo LJS; Zhao JT; Gild ML; Glover AR; Sidhu SB
Mol Cell Endocrinol; 2018 Jul; 469():48-53. PubMed ID: 28315378
[TBL] [Abstract][Full Text] [Related]
18. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G
Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440
[TBL] [Abstract][Full Text] [Related]
20. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
